2076 - Wahroonga - Sydney Adventist Hospital (COMPLETED)2485 - Tweed Heads - The Tweed Hospital (COMPLETED)2640 - Albury - Border Medical Oncology Research Unit (COMPLETED)

3000 - Melbourne - Peter MacCallum Cancer Centre (COMPLETED)3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (COMPLETED)3165 - East Bentleigh - Peter MacCallum Cancer Centre Moorabbin Campus (COMPLETED)

QLD4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (COMPLETED)

ACTRN12625000361404

A Phase 1, Multicentre, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FO-004 in Patients with advanced solid tumours.

ACTRN12625000309482

Accelerated Partial breast irradiation Using external beam Volumetric Modulated Arc Therapy (VMAT): a randomised non-inferiority trial of 30 Gy versus 26 Gy in five fractions investigating patient-reported outcomes. (PUMA)

ACTRN12624001230549

An assessment of cancer outcomes post cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases with the use of a personalised aproach to choice of intraperitoneal chemotherapy agent individualised to a patient's specific tumour sensitivity in-vitro.

ACTRN12623001077651

A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination with Anticancer Treatments in Patients with Solid Malignancies - Module 2. (EMITT-1)

ACTRN12623000104651

Phase I Trial of the Safety and Efficacy of Deflexifol for Refractory or Recurrent Paediatric Central Nervous System (CNS) Tumours (DART)

ACTRN12622000083796

Medicinal Cannabis (MedCan 3) – a randomised, multicentre, double blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer (20))

ACTRN12622000037707

A prospective, multicentre, randomised, blinded, two-arm parallel trial of Medicinal Cannabis Products for symptom burden in children with advanced cancer (MINI)

ACTRN12621001419853

A Phase 1 Dose Escalation and Dose Expansion Open-label, Multicenter, Study of OP-1250 in Combination with the CDK4/6 Inhibitor Palbociclib in Adult Subjects with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer (OP-1250-002)

ACTRN12621000227897

Not Applicable

Feasibility of Magnetic Resonance Imaging guided stereotactic reirradiation in patients who have previously received radiation for prostate cancer and have biochemical and local recurrence of cancer within the prostate (PRIUS-MR)

ACTRN12619000079145

A Phase I Study of Autologous CD19 Specific Chimeric Antigen Receptor T-cells for Therapy of Relapsed and Refractory B-cell Leukaemia and Lymphoma (The-AutoCAR19-Trial)

NCT06909825

A Phase 2, Open-label, Multi-centre Study of FPI-2265 (225Ac-PSMA-I&T) and Olaparib in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC) (FPI-2265-203)

NCT06128629

MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) (ITL-2001-CL-301)

NCT05828589

A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of Bcl-2 Inhibitor BGB-21447 in Patients With Mature B-Cell Malignancies (CT-2023-CTN-05421-1--BGB-21447-101)

NCT03662126

A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) Who Are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment (BOREAS)

ACTRN12622001339741

A Phase I, Open-label, Multicenter, First in Human Study to Evaluate the Safety and Tolerability of HH3806 in Patients with Advanced Malignancies (HH3806-A101)

ACTRN12621000639820

The activity and tolerability of Aromatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic gynaecological neoplasms (PARAGON-II) .

PD-1/PD-L1	28%
PD-1	24%
oestrogen axis	11%
PD-L1	9%
androgen axis	9%
VEGF	8%
AR	8%
ER	7%
TIGIT	7%
CDK4	6%
ERBB2	6%
CYP17A1	6%
PARP	6%
CDK6	5%
VEGFA	4%
KRAS	4%
KRAS G12C	4%
Trop2	3%
PARP1-selective	3%
CD20	3%
CTLA4	3%
MET	3%
VEGFR2	3%
Nectin4	3%
cereblon	3%
Bcl2	3%
EGFR	3%
ERBB3	3%
KIT	2%
RET	2%
VEGFR	2%
VEGFR1	2%
VEGFR3	2%
KLK2	2%
FR-alpha	2%
EZH2	2%
ERAP1	2%
BCMA	2%
BTK	2%
LHRH	2%
SMO	2%
HPK1	2%
WEE1	2%
LAG3	2%
AXL	1%
ROS1	1%
CDK4 selective	1%
FGFR3	1%
KAT6	1%
mTOR	1%
mTORC1	1%
IDH1	1%
IDH1 R132	1%
GDF15	1%
CD38	1%
proteasome	1%
PI3K delta	1%
CLDN6	1%
CEACAM5	1%
FGFR2	1%
FGFR2b	1%
PRMT5	1%
ER alpha	1%
AKT	1%
AKT1	1%
B7H3	1%
BRAF	1%
CRAF	1%
FAK	1%
MEK	1%
RAF	1%
pan-RAF	1%
MUC18	1%
DNA-dependent protein kinase	1%
CD93	1%
gp100	1%
CDK2	1%
CS1	1%
CD44v9	1%
CLDN18.2	1%
CD19	1%
ROR1	1%
B7H4	1%
TP53	1%
TP53 Y220C	1%
OX40	1%
PDGFR	1%
TIM3	1%
CD22	1%
GnRH	1%
PSMA	1%
TTR	1%
MDM2	1%
BET	1%
PI3Kalpha	1%

ARTICANZ - Beta (ver 0.91)

Search results

Filters